



Tel: +1 (425) 247-3088 Fax: +1 (425) 650-9990

Email: info@seattle-genova.com Web: www.seattle-genova.com Address: 18110 SE 34TH ST STE 455, Vancouver, WA 98683

BioActive Human CCND3 amplification Recombinant Protein,Fc Tag

Catalog Number:SGRP00695

DESCRIPTION	
Product Name	BioActive Human CCND3 amplification Recombinant Protein,Fc Tag
Gene Name	CCND3
Source	Full length Human CCND2 amplification, expressed in HEK293 cells.
Alternative names	
SPECIFICATIONS	
Biological Activity	Fully biologically active
Purity	> 95% by SDS-PAGE & HPLC
Endotoxin Level	< 1.0 EU per µg protein as determined by the LAL method
Expression System	HEK293 Cells
Format	Recombinant
Species	Human
Predicted MW	
Actual MW	
Applications	Sandwich ELISA Functional Studies Mass Spectrometry SDS-PAGE HPLO
Form	Lyophilized from sterile PBS, pH 7.78
Concentration	N/A
Stability and Storage	Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution	Reconstitute with Phosphate Buffered Saline.
BACKGROUND	
Gene Accession	P30281
Gene Alias	Protein names Recommended name G1/S-specific cyclin-D3 1 Publication Gene names Name CCND3 1 PublicationImported



Seattle Genova

Tel: +1 (425) 247-3088 Fax: +1 (425) 650-9990

Email: info@seattle-genova.com Web: www.seattle-genova.com Address: 18110 SE 34TH ST STE 455, Vancouver, WA 98683

0.59% of AACR GENIE cases, with breast invasive ductal carcinoma, lung adenocarcinoma, osteosarcoma, esophageal adenocarcinoma, and colon adenocarcinoma having the greatest prevalence.

Background

Cyclin D3 (CCND3) is a gene that encodes a protein that functions in the regulation of CDK kinases in the cell cycle. Fusions, missense mutations, nonsense mutations, silent mutations, and frameshift deletions and insertions are observed in cancers such as endometrial cancer, skin cancer, and stomach cancer. CCND3 is altered in 1.11% of all cancers with lung adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, diffuse large B-cell lymphoma, not otherwise specified, and esophageal adenocarcinoma having the greatest prevalence of alterations. CCND3 Amplification is present in